GRACE (Gender, Race And Clinical Experience): 48-week results of darunavir/r-based therapy in the largest trial in north america to focus on treatment-experienced women
Autor
Squires, Kethleen
Currier, Judith
Averitt Bridge, Dawn
Hagins, Debbie
Zorrilla, Carmen
Ryan, Robert
Falcon, Ron
Tennenberg, Alan
Mrus, Joseph
Tipo
PresentationFecha
2009-07-19Metadatos
Mostrar el registro completo del ítemResumen
Women account for an increasing proportion of patients living with HIV/AIDS in the United States (US) yet data on the efficacy and safety of antiretrovirals (ARVs) in women are limited.
– Several challenges, including socioeconomic factors, have led to diffi culties in recruiting and retaining women in ARV clinical trials
• Darunavir (DRV; PREZISTA®), a protease inhibitor (PI) combined with a low dose of ritonavir (DRV/r), has been approved for use in the US as a therapeutic option for treatment-experienced, treatment-naïve and pediatric (aged 6 to <18 years) HIV-infected patients3
• We report 48-week results from the primary analysis of the GRACE (Gender, Race And Clinical Experience) trial, which was designed to enroll a high proportion of treatment-experienced women, in order to assess sex-based differences in the effi cacy and safety of DRV/r-based therapy
– Analyses by race will be presented elsewhere